## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No. 6,884,879 – § 156 Unit: OPLA

Serial No.: **08/ 908,469** 

Confirmation No.: 9546

Filed: 25 August 2006
First Inventor: M. BACA

Patent Owner: Genentech, Inc.

For: Anti-VEGF antibodies

Application for patent term extension under 35 U.S.C. § 156

## Mail Stop Hatch-Waxman PTE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## ELECTION UNDER 37 C.F.R. § 1.785(b)

Sir:

This letter responds to the Notice of Final Determination and Requirement for Election mailed in the captioned application for patent term extension on 26 March 2009. The Notice observes that applicant filled applications to extend the terms of U.S. Patent Nos. 6,407,213, 6,884,879, and 7,060,269 based on the regulatory review period for LUCENTIS®. The Notice further states a requirement that applicant elect one of the patents to receive a term extension certificate within a period of one month of the date of the Notice. This election is filled within the stated period and is therefore timely.

Pursuant to § 1.785(b), applicant elects U.S. Patent No. 6,407,213 to receive a certificate of extension under § 1.780 and 35 U.S.C. § 156(e)(1). Applicant requests that the Director proceed to issue a certificate of extension of that patent based on the regulatory review period for LUCENTIS®, as indicated in the Notice of Final Determination and Requirement for Election issued in the application for patent term extension in the record of U.S. Patent No. 6.407.213.

We believe that no fee is due in respect of this election. However, the Director is requested to debit any fee required for entry or consideration of this paper from our Deposit Account No. 18-1260.

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347 Attorney for Genentech, Inc.

24 April 2009

SIDLEY AUSTIN LLP 1501 K Street, NW Washington, DC 20005

tel. (202) 736-8818 fax (202) 736-8711